Premium
Pharmacokinetics of actinomycin 0 in patients with malignant melanoma
Author(s) -
Tattersall M.H.N.,
Sodergren J. E.,
Sengupta S. K.,
Trites D. H.,
Modest E. J.,
Frei Emil ,
Publication year - 1975
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1975176701
Subject(s) - pharmacokinetics , melanoma , medicine , pharmacology , cancer research
The distribution and excretion of tritiated actinomycin D have been determined in 3 adult patients with disseminated malignant melanoma. In the blood, the drug was preferentially taken up into nucleated cells. The urinary and fecal excretion was prolonged and only about 30% of the dose of actinomycin was recovered in 9 days. There was evidence that the drug was concentrated in bone marrow and tumor cells, but did not readily cross the blood‐brain barrier. The long tissue half‐life of actinomycin D suggests that an intermittent schedule of administration would be the most effective.